How much does one month of amivantamab treatment cost?

Amivantamab (amivantamab) is a bispecific antibody drug developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. It has attracted widespread attention in the field of oncology in recent years. This drug is mainly used for patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. This type of mutated lung cancer has limited effect in traditional EGFR inhibitor treatment. Therefore, the emergence of evantumumab is regarded as an important breakthrough in precision medicine. With its launch in China, patients are particularly concerned about drug prices and actual medication costs.

The trade name of evantumumab currently on the market in China is "Carestream", the specification is 350mg/bottle, and the price of a single box may be more than 7,000 yuan. Since it has not been included in the scope of medical insurance reimbursement, patients need to bear all drug expenses out of their own pocket, which means that the cost of one month of treatment will fluctuate greatly due to differences in drug dosage and course of treatment. Evantumumab is administered by intravenous infusion, and the dose is usually higher at the beginning of treatment. The frequency of subsequent maintenance therapy can be adjusted based on weight and clinical response, which also directly affects the overall cost per month. Based on conventional clinical dosage estimates, one month's medication may cost tens of thousands of yuan, which is a considerable burden for many families.

In comparison, the price of evantumumab in overseas markets is also not low. In European and American countries, because this drug is an innovative bispecific antibody, its research and development costs and approval threshold are high, and its pricing is generally maintained at a high level. Commercial insurance or public medical insurance in some countries can share the price of drugs to reduce patients' financial pressure. However, in a domestic environment that is not yet covered by medical insurance, patients can only solve the problem of high drug expenses through self-pay or commercial insurance reimbursement. It is worth noting that as time goes by and market competition intensifies, the price of evantuzumab may be gradually adjusted.

Reference materials:https://www.rybrevant.com/